Javier Gallego

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2674314/publications.pdf

Version: 2024-02-01

34	605	623188	610482
papers	citations	14	24
		h-index	g-index

34	34	34	997
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry. British Journal of Cancer, 2017, 117, 775-782.	2.9	77
2	First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD). European Journal of Cancer, 2017, 81, 191-202.	1.3	68
3	Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab. British Journal of Cancer, 2017, 116, 1526-1535.	2.9	46
4	Clinical Impact of Presurgery Circulating Tumor DNA after Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer: A Biomarker Study from the GEMCAD 1402 Trial. Clinical Cancer Research, 2021, 27, 2890-2898.	3.2	44
5	Surgery for metastases for esophageal-gastric cancer in the real world: Data from the AGAMENON national registry. European Journal of Surgical Oncology, 2018, 44, 1191-1198.	0.5	42
6	A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features. BMC Cancer, 2015, 15, 60.	1.1	41
7	SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018). Clinical and Translational Oncology, 2019, 21, 46-54.	1.2	40
8	SEOM clinical guideline for the diagnosis and treatment of gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJA) (2019). Clinical and Translational Oncology, 2020, 22, 236-244.	1.2	28
9	Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials. Journal of Cancer Research and Clinical Oncology, 2018, 144, 321-335.	1.2	27
10	Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial. European Journal of Cancer, 2021, 145, 158-167.	1.3	26
11	Multistate Models: Accurate and Dynamic Methods to Improve Predictions of Thrombotic Risk in Patients with Cancer. Thrombosis and Haemostasis, 2019, 119, 1849-1859.	1.8	24
12	Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer. Gastric Cancer, 2017, 20, 465-474.	2.7	20
13	Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in first-line treatment of advanced gastric cancer: real-world data from the AGAMEMON National Cancer Registry. Gastric Cancer, 2018, 21, 96-105.	2.7	16
14	Identification of gene expression profiling associated with erlotinib-related skin toxicity in pancreatic adenocarcinoma patients. Toxicology and Applied Pharmacology, 2016, 311, 113-116.	1.3	15
15	Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry. PLoS ONE, 2020, 15, e0235848.	1.1	14
16	Causal considerations can inform the interpretation of surprising associations in medical registries. Cancer Investigation, 2021, , 1-27.	0.6	11
17	Biomarkers in pancreatic ductal adenocarcinoma. Clinical and Translational Oncology, 2017, 19, 1430-1437.	1.2	10
18	Optimal duration of first-line chemotherapy for advanced gastric cancer: data from the AGAMENON registry. Clinical and Translational Oncology, 2020, 22, 734-750.	1.2	8

#	Article	IF	Citations
19	SEOM-GEMCAD-TTD Clinical Guideline for the diagnosis and treatment of esophageal cancer (2021). Clinical and Translational Oncology, 2022, 24, 658-669.	1.2	8
20	Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients. Neoplasia, 2018, 20, 678-686.	2.3	7
21	Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy asÂpreoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long termÂresults. BMC Cancer, 2020, 20, 1164.	1.1	7
22	External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit?. Gastric Cancer, 2021, 24, 445-456.	2.7	7
23	External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110196.	1.4	5
24	Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab. Drugs in R and D, 2019, 19, 267-275.	1.1	4
25	Identification of Thrombosis-Related Genes in Patients with Advanced Gastric Cancer: Data from AGAMENON-SEOM Registry. Biomedicines, 2022, 10, 148.	1.4	4
26	Controversies in the treatment of RAS wild-type metastatic colorectal cancer. Clinical and Translational Oncology, 2021, 23, 827-839.	1.2	3
27	SEOM clinical guidelines for the treatment of oesophageal cancer. Clinical and Translational Oncology, 2011, 13, 520-524.	1.2	2
28	Impact of primary tumour location (PTL) on outcomes in patients (pts) with metastatic colorectal cancer (mCRC) undergoing first-line panitumumab (Pmab) + FOLFIRI treatment .. Journal of Clinical Oncology, 2018, 36, 820-820.	0.8	1
29	Towards an optimal treatment strategy for patients with oesophageal cancer. Clinical and Translational Oncology, 2008, 10, 131-133.	1.2	0
30	Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry. , 2020, 15, e0235848.		0
31	Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry. , 2020, 15, e0235848.		0
32	Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry. , 2020, 15, e0235848.		0
33	Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry. , 2020, 15, e0235848.		0
34	Cell-free circulating tumor DNA in colorectal cancer: a proof of concept with simplified methodology. Clinical and Translational Oncology, 2022, , .	1.2	0